United States · Venture startup

Who invested in Evergreen Nephrology

One round we have observed, with the 0 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

Healthcare

Funding summaryUpdated 31 Oct 2026

$130Mraised across 1 round since 2025, from 1 source

Latest round
Venture, $130MJan 2025
Investors
0
See who backed them

The rounds

  1. Jan 2025
    Venture$130M

    No investor was named in the report.

    Source recorded

Founders and team

From Evergreen Nephrology's own website: 8 on the team.

  • Heather TraftonChief Executive Officer
  • Brian PaloChief Financial Officer
  • Eugenia TimmChief Operating Officer
  • Greeshma ShettyChief Clinical Officer
  • Ron MargalitChief Information Officer
  • Scott LloydChief Development and Strategy Officer
  • Tim PfledererChief Medical Officer
  • Alex DuPuisGeneral Counsel

Also claim to have backed them

These 3 firms list Evergreen Nephrology as a portfolio company on their own websites, but no report of a round names them. They are the firms' own claims, kept apart from the rounds above.

Martin VenturesVC firmPer its own site
K2 HealthVenturesPrivate equityPer its own site
Health2047 Capital PartnersVC firmPer its own site

Quick answers about Evergreen Nephrology

How much has Evergreen Nephrology raised?

Evergreen Nephrology has raised $130M across 1 round since 2025.

When did Evergreen Nephrology last raise?

Evergreen Nephrology's most recent round was a Venture of $130M in Jan 2025.

What was Evergreen Nephrology's biggest round?

Its most recent round, $130M in Jan 2025, is also its largest on record.

What stage is Evergreen Nephrology at?

Evergreen Nephrology's latest named round is a Venture, in Jan 2025.

Where is Evergreen Nephrology based?

Evergreen Nephrology is based in the United States.

Companies like Evergreen Nephrology

In the same sector, and raised in the last eighteen months.

Find investors like these

Search every investor by what they have actually funded, then narrow to your stage and market. Free.